A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
NCT06431607 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 845
Last updated 2026-03-10
Summary
The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).
Conditions
- Influenza, Human
Interventions
- BIOLOGICAL
-
F2G22B/DL001Z
Study intervention was administered intramuscularly at Day 1.
- BIOLOGICAL
-
F2H23D/DL001Z-NH
Study intervention was administered intramuscularly at Day 1.
- BIOLOGICAL
-
F2H23B/DL001Z-NH
Study intervention was administered intramuscularly at Day 1.
- BIOLOGICAL
-
F2H23H/DL001Z
Study intervention was administered intramuscularly at Day 1.
- COMBINATION_PRODUCT
-
FDQ23A-NH (Flu D-QIV)
Control Vaccine was administered intramuscularly at Day 1.
- BIOLOGICAL
-
GSK5800544A
Study intervention was administered intramuscularly at Day 1.
- COMBINATION_PRODUCT
-
Flu D-TIV
Control Vaccine was administered intramuscularly at Day 1.
- BIOLOGICAL
-
F2H23A/DL001Z-NH
Study intervention was administered intramuscularly at Day 1.
- BIOLOGICAL
-
F2H23G/DL001Z
Study intervention was administered intramuscularly at Day 1.
- COMBINATION_PRODUCT
-
Fluzone HD Quadrivalent
Control vaccine was administered intramuscularly at Day 1.
- COMBINATION_PRODUCT
-
Fluzone HD
Control vaccine was administered intramuscularly at Day 1.
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-05-23
- Primary Completion
- 2024-12-27
- Completion
- 2025-06-04
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older
NCT00753272 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
NCT05827068 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age
NCT01934127 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People
NCT00992784 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older
NCT04789577 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
NCT05333289 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
NCT06864143 ·Status: COMPLETED ·Phase: PHASE2
-
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
NCT05827978 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
NCT04956575 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older
NCT00760617 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
NCT00765076 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
NCT06508320 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults
NCT04782323 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age
NCT01999842 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)
NCT01204671 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly
NCT00938392 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
NCT06087640 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Evaluate an Influenza Vaccine Candidate
NCT00321373 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
NCT06602024 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix
NCT00693706 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)
NCT00812019 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
NCT06097273 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years
NCT03275389 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults
NCT04576702 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine
NCT01201902 ·Status: COMPLETED ·Phase: PHASE3